Lionetti, Raffaella <br/><br/>
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.  [electronic resource] 

 -  Clinical transplantation  02 2018 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1399-0012 
<br/><br/><label>Standard No.: </label>10.1111/ctr.13165  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--therapeutic use<br/>Carbamates<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Hepacivirus--isolation & purification<br/>Hepatitis C--complications<br/>Humans<br/>Imidazoles--therapeutic use<br/>Italy<br/>Liver Cirrhosis--drug therapy<br/>Liver Transplantation--adverse effects<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Prospective Studies<br/>Pyrrolidines<br/>Recurrence<br/>Ribavirin--therapeutic use<br/>Sofosbuvir--therapeutic use<br/>Valine--analogs & derivatives